Magellan Rx Management and Trapelo Health to Offer Precision Oncology Platform for Next-Generation Care
April 08 2021 - 6:30AM
Business Wire
Collaboration gives Magellan Rx customers a
first-of-its-kind solution to address the complexities of precision
medicine
Magellan Rx Management, a division of Magellan Health, Inc.
(NASDAQ: MGLN), and Trapelo Health, today announced that they are
collaborating to champion a more comprehensive, integrated approach
to value-based care in the new era of precision oncology
treatments.
The collaboration combines the unique strengths of the two
organizations: Magellan Rx’s comprehensive oncology management
solution, and the Trapelo® precision-medicine platform that enables
fast, precise test and treatment decision support, including test
order management, results interpretation and streamlined prior
authorizations.
To learn more, listen to an in-depth conversation with
leaders from both companies on the Precision Medicine
Podcast.
The role of actionable molecular tests is growing significantly
in the selection of advanced cancer therapies. The provision of
high-quality cancer care requires the appropriate identification of
patients to be tested while ensuring the correct tests are ordered
for those patients. Accurate interpretation of the test results,
based on current medical evidence is crucial. Clinical data is
being published at such an unprecedented pace that providers and
payers need access to a shared, unbiased decision-support
technology.
The Trapelo decision-support platform ensures comprehensive,
personalized testing for every cancer patient every time while
allowing payers autonomy regarding contracted lab selection. Using
Trapelo, oncologists will be able to order the appropriate
molecular tests and receive results faster through a simplified and
automated prior authorization process. Treatment selection is also
streamlined by identifying relevant treatments based on molecular
test results, evidence-based guidelines and clinical trials.
Trapelo's patent-pending technology incorporates health plan policy
and eliminates unnecessary medical redocumentation to speed
approvals for both cancer genomic testing and drug therapy
selection.
“We recognize that contemporary oncology care requires changes
in the approach to oncology management,” said Caroline Carney,
M.D., Chief Medical Officer of Magellan Health and Magellan Rx
Management. “This collaboration allows us to extend the value of
the services we can provide to our health plan customers, and
strengthens our shared commitment to ensuring that every patient
receives the opportunity for the best possible outcome.”
This solution will support Magellan Rx Management’s medical
pharmacy program which offers comprehensive, patient-focused
oncology solutions and cost savings so that payers can deliver true
value and improved quality of life. Magellan Rx’s offering includes
integrated, flexible interventions that address the many facets of
cancer care, such as: guideline-supported prior authorization; drug
wastage; personalized dosing; oral oncology management;
post-service claim edits; provider network management; specialty
formulary solutions; site of service; and holistic patient care
management.
“We are delighted to be working with Magellan. This gives us a
significant opportunity to advance our vision for a more
collaborative approach in oncology that streamlines workflow and
eases administrative burden for providers, labs and payers while
improving patient access and outcomes,” added Clynt Taylor, CEO of
Trapelo Health.
About Trapelo Health: Trapelo Health, a wholly-owned
subsidiary of NeoGenomics Bioinformatics, is an information
technology company on a mission to address the challenges that
result from rapid changes in the science, technology and business
of next-generation cancer care. Its product, Trapelo, is a win-win
solution for doctors, labs and payers that need real-time,
evidence-based information and full transparency to make
patient-based decisions faster. As part of this commitment, Trapelo
is the lead sponsor of The Precision Medicine Podcast a media
platform that brings together industry leaders to help accelerate
the effective use of precision medicine for cancer care.
About Magellan Rx Management: Magellan Rx Management, a
division of Magellan Health, Inc., is shaping the future of
pharmacy. As a next-generation pharmacy organization, we deliver
meaningful solutions to the people we serve. As pioneers in
specialty drug management, industry leaders in Medicaid pharmacy
programs and disruptors in pharmacy benefit management, we partner
with our customers and members to deliver a best-in-class
healthcare experience.
About Magellan Health: Magellan Health, Inc., is a leader
in managing the fastest growing, most complex areas of health,
including special populations, complete pharmacy benefits and other
specialty areas of healthcare. Magellan supports innovative ways of
accessing better health through technology, while remaining focused
on the critical personal relationships that are necessary to
achieve a healthy, vibrant life. Magellan's customers include
health plans and other managed care organizations, employers, labor
unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.
(MGLN-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210408005126/en/
Media: Lilly Ackley, ackleyl@magellanhealth.com, (860)
507-1923 Investors: Darren Lehrich,
lehrichd@magellanhealth.com, (860) 507-1814 Media: Karan
Cushman, Chief Marketing Officer, kcushman@trapelohealth.com
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Magellan Health (NASDAQ:MGLN)
Historical Stock Chart
From Apr 2023 to Apr 2024